Cationic Glyco-nangels for Epidermal Growth Factor Receptor (EGFR) specific siRNA delivery in Ovarian Cancer Cells

Marya Ahmed[†], Phanphen Wattanaarsakit[§], Ravin Narain^{†*}

[†]Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 2G6,

Canada

*Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences,

Chulalongkorn University, Phyathai Road, Pathumwan, Bangkok, Thailand

 Table S1. Preparation of nanogels

Nanogels	PEGMA or NIPAM (mg)	AEMA (mg)	Macro-CTAs (mg)	CL (mg)	ACVA (mg)
NGA1	301	66	380	60	2
NGA2	200	73	165	133	1.6

NGA1: GAEMA₆₃-b-(MeODEGM-st-AEMA-st-CL)₁₀₀



NGA2: GAPMA₅₇-b-(NIPAM-st-AEMA-st-CL)₂₀₀




Figure S1: Complexation fo β-galactosidase DNA with cationic glyco-nanogels, at varying w/w ratios.




Figure S2: Size of nanogel-siRNA complexes in OMEM media in the absence and presence of serum proteins, as determined by DLS analysis.